Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

Shares of Axsome Therapeutics ( AXSM 4.07%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Securities exhibited confidence in Axsome Therapeutics (NASDAQ:AXSM) by increasing the company's price target from $137.00 to $195.00. The firm has maintained an Outperform rating on the stock. This ...

This strategy enables Pfizer to maintain a strong foothold in the generic drug market while also protecting its revenue ...

AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United ...

TD Cowen adjusted its outlook on Axsome Therapeutics (NASDAQ:AXSM), a $6.16 billion market cap company, by increasing the price target to $190 from the previous $155, while maintaining a Buy rating on ...

TD Cowen raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $155 and keeps a Buy rating on the shares. The company ...

South Korean pharmaceutical and biotechnology companies are on edge as U.S. President Donald Trump signals the introduction ...

The grants have been the source of new treatments for cancer, heart disease, diabetes, strokes and H.I.V.; wonder drugs like ...